These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations. Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558 [TBL] [Abstract][Full Text] [Related]
10. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER? Reed RC; Dutta S Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728 [TBL] [Abstract][Full Text] [Related]
11. Inverse correlation of valproic acid serum concentrations and quality of life in adolescents with epilepsy. Jakovljevic MB; Jankovic SM; Jankovic SV; Todorovic N Epilepsy Res; 2008 Aug; 80(2-3):180-3. PubMed ID: 18495431 [TBL] [Abstract][Full Text] [Related]
12. Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium. Reed RC; Dutta S Am J Health Syst Pharm; 2004 Nov; 61(21):2284-9. PubMed ID: 15552636 [TBL] [Abstract][Full Text] [Related]
13. Subtherapeutic valproic acid plasma concentrations under concomitant dipyrone therapy in an epilepsy patient-a case report. Morath B; Green K; Zaradzki M; Heid J; Karck M; Hoppe-Tichy T Eur J Clin Pharmacol; 2018 May; 74(5):675-677. PubMed ID: 29362820 [No Abstract] [Full Text] [Related]
15. Developmental and therapeutic pharmacology of antiepileptic drugs. Miura H Jpn J Psychiatry Neurol; 1993 Jun; 47(2):169-74. PubMed ID: 8271538 [No Abstract] [Full Text] [Related]
16. Different serum concentrations of steady-state valproic acid in two sustained-release formulations. Yasui-Furukori N; Saito M; Nakagami T; Niioka T; Sato Y; Fujii A; Kaneko S Psychiatry Clin Neurosci; 2007 Jun; 61(3):308-12. PubMed ID: 17472600 [TBL] [Abstract][Full Text] [Related]
17. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy. Reed RC; Dutta S; Liu W Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children. Panomvana Na Ayudhya D; Suwanmanee J; Visudtibhan A Am J Ther; 2006; 13(3):211-7. PubMed ID: 16772762 [TBL] [Abstract][Full Text] [Related]
19. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage. Bondareva IB; Jelliffe RW; Sokolov AV; Tischenkova IF J Clin Pharm Ther; 2004 Apr; 29(2):105-20. PubMed ID: 15068399 [TBL] [Abstract][Full Text] [Related]
20. A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy. Rodrigues C; Chhun S; Chiron C; Dulac O; Rey E; Pons G; Jullien V Eur J Clin Pharmacol; 2018 Jun; 74(6):793-803. PubMed ID: 29564480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]